Risk factors for breakthrough invasive fungal infection during secondary prophylaxis

200870 citationsJournal Articlebronze Open Access

Authors

Oliver A. Cornely · University of Cologne

Angelika Böhme · Goethe University Frankfurt

Dietmar Reichert · Klinikum Oldenburg

Stefan Reuter · University Hospital Ulm

Georg Maschmeyer · Charité - Universitätsmedizin Berlin

Johan Maertens · Universitair Ziekenhuis Leuven

Dieter Buchheidt

Abstract

Duration of neutropenia, high-dose cytarabine, prior antibiotic therapy and a partial response to the first IFI therapy were risk factors for recurrent IFI and should be considered in AML patients with prior pulmonary IFI undergoing further chemotherapy.

Topics & Keywords

Antifungal resistance and susceptibility Fungal Infections and Studies Neutropenia and Cancer Infections

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Antimicrobial Chemotherapy

Volume 61, Issue 4, pp. 939-946

DOI: 10.1093/jac/dkn027

Field-Weighted Citation Impact: 4.36